The epidermal growth factor receptor (EGFR; ErbB1) is a member of the epidermal growth factor RTK (receptor tyrosine kinases) family, along with HER2/neu (ErbB2), ErbB3 (HER3), and ErbB4 (HER4). The extracellular ligand-binding ectodomain, the single chain transmembrane domain, and the intracellular tyrosine kinase domain make up the EGFR, which is located at the cell surface. Epidermal growth factor (EGF), transforming growth factor (TGF-α), amphiregulin, heparin-binding EGF, and betacellulin are just a few of the ligands that bind to and activate the EGFR.
The tyrosine kinase domain is activated by the receptors' formation of homo- or heterodimeric complexes after ligand binding. The Ras-Raf-MAP kinase, PI-3K/Akt, PKC, and Stat/Jak signaling pathways are all activated as a result of the dimerization and autophosphorylation of EGFR. The EGFR is activated to control cellular survival, differentiation, and proliferation. The EGFR has been derided as a proto-oncogene primarily because of its function in encouraging cell proliferation and preventing apoptosis.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V51518 | (E/Z)-AG490 | 134036-52-5 | (E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is the racemate of (E)-AG490 and (Z)-AG490. |
|
V87036 | (Rac)-JBJ-04-125-02 acetate | (Rac)-JBJ-04-125-02 acetate is the racemate of JBJ-04-125-02, a potent, mutant-selective, allosteric and orally active EGFR inhibitor. | |
|
V88019 | (Z)-RG-13022 | 149286-90-8 | (Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits EGFR TK activity and inhibits EGF-stimulated cultured cell growth. |
|
V92474 | 13(S)-HPODE | 33964-75-9 | 13(S)-HPODE is a linoleic acid metabolite found in some plants and mammals. |
|
V102893 | 4-Epidoxycycline | 6543-77-7 | |
|
V101861 | 4-Methyl erlotinib | 1346601-52-2 | 4-Methylerlotinib is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. |
|
V97045 | 4-Methyl erlotinib (Standard) | 1346601-52-2 | 4-Methyl Erlotinib (Standard) is the analytical standard for 4-methyl Erlotinib. |
|
V106376 | Anti-Human/Rat HER2 (neu) Antibody (7.16.4) | ||
|
V100619 | Antiproliferative agent-54 | 1240322-54-6 | Antiproliferative agent-54 (compound 6z) is an inhibitor of multiple kinases, such as ABL WT, B-RAF, EGFR, HCK, LYN A, and SRC, with IC50 of 6-50 nM. |
|
V99924 | Asandeutertinib | 1638281-46-5 | Asandeutertinib (Osimertinib-d3; AZD-9291-d3) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor effects. |
|
V104381 | Avitinib maleate dihydrate | 1822357-78-7 | |
|
V89060 | AZ14133346 | AZ14133346 (compound 36) is a potent and selective EGFR exon 20 insertion inhibitor with IC50 of 85 nM. | |
|
V106421 | Azerutamig | ||
|
V86152 | Befotertinib mesylate (D-0316 mesylate) | 2226167-02-6 | |
|
V88962 | BI-4732 | 2769715-68-4 | BI-4732 is a potent inhibitor of EGFR activating (E19del and L858R) and T790M mutations with high blood-brain barrier permeability and targets a broad range of EGFR mutations, including C797S. |
|
V103408 | BIHC | 1642826-40-1 | |
|
V88961 | Biotin HER-2 substrate peptide | Biotin HER-2 substrate peptide is a substrate for HER4 and HER2/NEU tyrosine kinases, with a Km value of 60 μM for the HER2/NEU kinase domain. | |
|
V104885 | BML-265 | 183321-62-2 | |
|
V98031 | BPI-15086 | 1644502-33-9 | BPI-15086 is an oral, potent, irreversible, mutation-selective EGFR and T790M resistance-mutant tyrosine kinase inhibitor. |
|
V106388 | Calotatug |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
